Hims & Hers Stock Plummets Despite Major Share Repurchase Initiative

The telehealth company Hims & Hers Health has seen its share price collapse by 30% over the past month, a stark contrast to the confidence it aimed to project with the announcement of a substantial $250 million stock buyback program. This dramatic sell-off coincides with insider stock sales and occurs while the company’s valuation appears stretched to unprecedented levels, raising significant questions about its current market position.

Sky-High Valuation Raises Concerns

A primary concern for market participants is the company’s valuation. Hims & Hers shares are currently trading at a price-to-earnings (P/E) ratio ranging from 61 to 66. This figure stands in sharp relief against the healthcare sector’s average P/E of just 21.9. Even when measured against its direct competitors, who average a P/E of 28.4, the stock is valued at more than double the norm.

This significant premium implies that the market has already priced in a highly aggressive growth trajectory, leaving minimal room for any performance shortfalls. Although the firm positions itself as a comprehensive “healthcare infrastructure” provider rather than a simple telehealth service, this substantial deviation from industry benchmarks serves as a potent warning signal for potential investors.

Insider Selling During Market Turmoil

Adding fuel to the fire are recent transactions by company insiders. Chief Financial Officer Oluyemi Okupe sold 23,187 shares at an average price of $36.81 on November 19, 2025. While these sales were concurrent with the exercise of options, the decision to immediately liquidate a portion of the holdings into the open market sends a distinct message. For many observers, when senior executives sell during periods of high volatility and price decline, it often suggests limited near-term upside potential from the perspective of those with the most intimate knowledge of the business.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Buyback Fails to Halt Slide

The company’s board had authorized a new share repurchase program of $250 million on November 17, 2025, valid until November 2028. This initiative followed a previously completed $100 million buyback. The strategic move was clearly intended to instill market confidence and demonstrate a belief in the company’s intrinsic value.

However, the anticipated market reversal failed to materialize. Instead of rising, the stock continued its downward trajectory. The market’s tepid response to this capital allocation maneuver highlights deeper anxieties. Significant concerns persist about intensifying competition in the lucrative GLP-1 market for weight-loss medications and, more fundamentally, whether the current valuation can be justified at all.

The overarching message for investors is clear: financial engineering alone is insufficient to restore confidence. As long as the underlying fundamentals do not support the extreme valuation and corporate insiders are simultaneously cashing out, investor skepticism will likely prevail. Hims & Hers now faces mounting pressure to deliver on its growth promises; otherwise, the current market correction may have further to run.